> ## Content Index > Fetch the complete content index at: https://theainewsfiles.com/llms.txt > Use this file to discover other available public pages before exploring further. # Anthropic says it has partnered with six drug developers and started drug programmes of its own - URL: https://theainewsfiles.com/anthropic-claude-drug-development-six-partners/ - Published: 2026-10-28T20:26:10.000Z - Updated: 2026-10-28T20:26:10.000Z - Description: Anthropic reports deep research partnerships with six drug developers, plus programmes of its own, including one for rare childhood muscular dystrophy. It says the work is still early and mostly preclinical. - Author: J E Cowie - Tags: News On 27 October 2026, Anthropic published a research post on its work in drug development. It says its life sciences team has spent the past several months in "deep research partnerships" with six organisations developing new medicines: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. It also says it has begun drug discovery efforts of its own. Every figure below is Anthropic's account of the work, taken from its own post. The post links technical reports for most of the partner case studies. Anthropic itself writes: "All of this research is still at an early stage." It adds that so far the work is "mostly preclinical", meaning that for the most part the drugs are not yet being tested in humans. ## What Anthropic says it did with each partner Anthropic's argument is that the bottlenecks in drug development are spread across the whole process, from choosing a target to drafting regulatory filings and running trials. Its answer, in its words, is to get "deeply involved in real drug programs". The post gives a case study for each partner. *Bristol Myers Squibb is one of the six organisations named in Anthropic's post.* **Generate Biomedicines.** Generate wants to reengineer CAR T-cell therapy, which has historically helped treat blood cell cancers, so that it can treat solid tumours too. Anthropic says six Generate scientists used Claude Code to propose new designs for one part of the therapy's genetic instructions. One design was about 70% shorter than the standard version. In lab tests, Anthropic says, it let immune cells make roughly 10 times as many receptors, killed tumour cells more efficiently and kept the immune cells active for longer. **Divergence Labs.** The company is developing a food-allergy treatment that would detach IgE from immune cells, rather than only neutralising the IgE circulating in the blood, as standard medications do. Anthropic says Claude turned Divergence's goals into a design plan and then, largely autonomously, generated roughly 35,000 antibody designs in about a month. In early tests Divergence found three designs that could bind to IgE and 20 that could dislodge it, and three of those 20 appeared to dislodge IgE more than the standard medication. The next step Anthropic describes is a drug that combines the two: one part that binds IgE and another that dislodges it. **BigHat Biosciences.** BigHat pairs AI with an automated lab. Anthropic says Claude, connected to BigHat's lab data system, Reccy, proposed changes to two antibody-fragment leads, one aimed at cancer cells and one meant to keep a drug in the body longer. BigHat's lab made and tested about 1,010 variants in about 10 weeks. Compared with the originals, the best versions bound more than 10x more tightly. The cancer-targeting lead stayed in solution 18°C higher, and the longer-lasting-drug lead clumped more than 100x more slowly. **Enveda.** Anthropic says manufacturing chemists at Enveda spent up to 75% of their time on paperwork. Enveda built a system connecting its manufacturing documents to Claude. Across tests on 1,061 pages, Anthropic says, Claude caught all 11 issues human reviewers had spotted and flagged seven they had missed, cutting human review time by 89%, from over 25 hours to less than three. Claude also wrote first drafts of two regulatory documents. One took four hours, against about three months by hand. For the other, Enveda's standard human review found one minor error. **The Column Group.** The firm is establishing Pleiades, a new company that will use Claude to run many more, and more complex, drug programmes than is usual for a small team. Anthropic says Pleiades' first Claude skill, which helps assess whether drug targets are worth pursuing, has been evaluated on 45 target-disease pairs. **Bristol Myers Squibb.** This partnership is more recent. Anthropic says BMS is using Claude to assess the plans of an early-stage drug in clinical trials and to estimate the likelihood of those trials succeeding, with an expansion planned for 2027\. The post quotes Michael Pourdehnad, MD, whom it identifies as Senior Vice President, Head of Early Clinical Development, Hematology, Oncology and Cell Therapy: "From a single prompt, Claude generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete." ## Anthropic's own programmes The post says Anthropic has also "started drug discovery efforts of our own, including programs for rare childhood forms of muscular dystrophy, where Claude handles much of the scientific and operational work." As part of that, Anthropic says it has acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy. According to the post, its founder, Cody Tranbarger, used Claude to organise contracts, logistics and experiments with 11 external labs, and Mithril took a possible treatment for one form from an idea to promising results in mice in less than 18 months. Tranbarger is now at Anthropic and plans to start several new programmes. Anthropic writes that if his drug candidates continue to hold up, "we expect a drug to be ready to start clinical trials in humans as soon as late 2028." The post links a technical report on the Mithril work. ## Tools and access Alongside the case studies, Anthropic says it has rolled out Claude Science, an AI workbench for researchers, and is providing Claude credits for life scientists. It also describes the Life Sciences Verification Program, which lets trusted organisations use its most powerful models with more permissive versions of its safeguards. Anthropic says those safeguards are necessary to prevent misuse but can impede legitimate biological research. It has also launched an open call for guest investigators in the life sciences. ## How to read it This is an announcement of results Anthropic reports from partner work, several of them with technical reports behind them, not a trial outcome. The figures are impressive on their face: one design about 70% shorter, 35,000 antibody designs in about a month, review time cut by 89%. But each describes a step in a long process, and Anthropic's own statement that the work is early and mostly preclinical sets the limit on what any of it shows today. The claim that would matter most, a drug in human trials, is one Anthropic puts at late 2028 at the earliest, and only if the candidates hold up. ## Sources ABAB News (2026) 'Anthropic Acquires One-Person Company Mithril and Advances Six Drug Development Collaborations', ABAB News, 27 October 2026, available at: [https://www.ababnews.com/en/news/e94f9a8f-f021-4e7c-b003-066e91fad8ff](https://www.ababnews.com/en/news/e94f9a8f-f021-4e7c-b003-066e91fad8ff?ref=theainewsfiles.com) (Accessed: 28 October 2026). Anthropic (2026) 'Early progress on accelerating drug development with Claude', Anthropic, 27 October 2026, available at: [https://www.anthropic.com/research/early-progress-drug-development](https://www.anthropic.com/research/early-progress-drug-development?ref=theainewsfiles.com) (Accessed: 28 October 2026). ## Picture credits - Top picture. Bristol Myers Squibb headquarters campus, Lawrenceville, NJ — photo: Coolcaesar, [CC BY-SA 3.0](https://creativecommons.org/licenses/by-sa/3.0/?ref=theainewsfiles.com) (via [Wikimedia Commons](https://commons.wikimedia.org/wiki/File:Bristolmyersprincetonfacility.jpg?ref=theainewsfiles.com))